Literature DB >> 8272194

Monoamine oxidase inhibition by L-deprenyl depends on both sex and route of administration in the rat.

M P Murphy1, P H Wu, N W Milgram, G O Ivy.   

Abstract

The monoamine oxidase B (MAO-B) inhibitor L-deprenyl, widely used to treat Parkinson's disease, has frequently been studied in animal models. We have examined the effects of several variables on activity levels of MAO-A and B in rat brain and liver following chronic (3 wks) treatment with L-deprenyl. Significant effects were observed for sex (females showed lower overall MAO-B activity in the liver), dose (MAO-A and B inhibition increased with dose, with females exhibiting greater sensitivity), route of administration (subcutaneous injection was more efficient than oral dosing), and dosing interval (MAO-B was significantly inhibited when dosing interval was increased to as long as 168 hours). Our results thus indicate that the effectiveness of L-deprenyl in vivo is dependent on several factors and that these must be taken into account in studies involving the benefits or risks of this drug.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8272194     DOI: 10.1007/bf00975051

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  34 in total

1.  Synthetic rates of monoamine oxidase in rat liver after clorglyine or deprenyl administration.

Authors:  T Egashira; K Kamijo
Journal:  Jpn J Pharmacol       Date:  1979-08

2.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

3.  Amine oxidase and amine metabolism.

Authors:  H BLASCHKO
Journal:  Pharmacol Rev       Date:  1952-12       Impact factor: 25.468

4.  Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment?

Authors:  B Ekstedt; K Magyar; J Knoll
Journal:  Biochem Pharmacol       Date:  1979-03-15       Impact factor: 5.858

5.  Cumulative effects of irreversible MAO inhibitors in vivo.

Authors:  A E Felner; P C Waldmeier
Journal:  Biochem Pharmacol       Date:  1979-04-01       Impact factor: 5.858

6.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

7.  Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets.

Authors:  D S Robinson; J M Davis; A Nies; C L Ravaris; D Sylwester
Journal:  Arch Gen Psychiatry       Date:  1971-06

8.  Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.

Authors:  P Riederer; C Konradi; V Schay; E Kienzl; G Birkmayer; W Danielczyk; E Sofic; M B Youdim
Journal:  Adv Neurol       Date:  1987

9.  Monoamine metabolism in human brain.

Authors:  D S Robinson; T L Sourkes; A Nies; L S Harris; S Spector; D L Bartlett; I S Kaye
Journal:  Arch Gen Psychiatry       Date:  1977-01

10.  Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.

Authors:  F Karoum; L W Chuang; T Eisler; D B Calne; M R Liebowitz; F M Quitkin; D F Klein; R J Wyatt
Journal:  Neurology       Date:  1982-05       Impact factor: 9.910

View more
  2 in total

Review 1.  The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog.

Authors:  N W Milgram; G O Ivy; E Head; M P Murphy; P H Wu; W W Ruehl; P H Yu; D A Durden; B A Davis; I A Paterson
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

2.  A mechanistic hypothesis of the factors that enhance vulnerability to nicotine use in females.

Authors:  Laura E O'Dell; Oscar V Torres
Journal:  Neuropharmacology       Date:  2013-05-17       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.